Lifecome Pharmaceuticals issued a clarification announcement stating that the company has not laid out any business or products related to brain-computer interfaces. The company noted that some self-media have labeled it a brain-computer interface concept stock, but its marketed product methylphenidate hydrochloride extended-release tablets are mainly used to treat attention deficit hyperactivity disorder, and the strategic cooperation framework agreement signed with Apon Medical is aimed at jointly exploring collaborative treatment solutions involving drugs and medical devices in the attention deficit hyperactivity disorder field. This cooperation will not have an impact on the company's performance. In addition, four of the company's products have been newly included in the National Essential Medicines List 2026 edition, but product sales are affected by factors such as market access, hospital admission, professional promotion, and policies, and there is uncertainty.
Hefei Lifeon Pharmaceutical Co LtdCompany clarifies it has no brain-computer interface business, contradicting concept stock labeling.
Jiangsu Apon Medical Technology Co Ltd Class AStrategic cooperation with Lifecome for ADHD treatment solutions, but no impact on performance stated.